These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 17229160

  • 21. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 22. Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients.
    Bellmunt J, Macià F, Malmusi D, Llorente JA, Carles J, Lloreta J, Foro P, Gelabert A, Albanell J, Castells X.
    Eur J Cancer; 2009 Nov; 45(16):2804-9. PubMed ID: 19625182
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S, Lawrentschuk N, Grills RJ, Neerhut G.
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [Abstract] [Full Text] [Related]

  • 28. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):36-9. PubMed ID: 19233568
    [Abstract] [Full Text] [Related]

  • 29. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD.
    Urology; 2007 Mar 01; 69(3):541-6. PubMed ID: 17382161
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H, Nishiyama K, Tanaka E, Maeda O, Meguro N, Kinouchi T, Usami M, Kakimoto K, Ono Y, Nishimura T.
    Anticancer Res; 2008 Mar 01; 28(6B):3913-20. PubMed ID: 19192649
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK, Adams MT, Motta J.
    Brachytherapy; 2008 Mar 01; 7(1):17-21. PubMed ID: 18201939
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N, Klotz L, Crook J, Goldenberg SL.
    Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527
    [Abstract] [Full Text] [Related]

  • 37. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV.
    Urology; 2007 Mar 01; 69(3):515-9. PubMed ID: 17382156
    [Abstract] [Full Text] [Related]

  • 38. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML.
    J Urol; 2008 May 01; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [Abstract] [Full Text] [Related]

  • 39. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG.
    BJU Int; 2007 Jan 01; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.